The clinical efficacy of PD-1 suppression and its ability to augment the effector function of the tumor-specific CD8+ T cells PD-1/PD-L1 inhibition ratio have broadened the opportunities for therapy in patients with previously untreatable malignancies or ineligible to traditional therapies [142]. Here, CD8A is linked to neoplasm.